Shares of Lupin were up over 2% at Rs 892 after hitting an all-time high of Rs 905 in intra-day trades today following a deal in which it will undertaking marketing of MSD's pneumonia prevention vaccine under a different brand name in India.
As part of the agreement, Mumbai-based Lupin will have a non-exclusive licence to market, promote and distribute MSD's 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in the country, Lupin Ltd said in a statement.
Pneumococcal disease is an infection caused by bacteria and it results in variety of pneumococcal diseases with pneumonia being the most common occurrence in adults.
MSD India operates in India via three separate legal entities MSD Pharmaceuticals Ltd, Organon India Ltd and Fulford India Ltd.
